Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Other Accumulated Expenses (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Other Accumulated Expenses for 8 consecutive years, with $135000.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 89.63% to $135000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $135000.0 through Dec 2025, down 89.63% year-over-year, with the annual reading at $135000.0 for FY2025, 89.63% down from the prior year.
  • Other Accumulated Expenses hit $135000.0 in Q4 2025 for Ligand Pharmaceuticals, roughly flat from $135000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.3 million in Q4 2024 to a low of $135000.0 in Q3 2025.
  • Historically, Other Accumulated Expenses has averaged $565500.0 across 4 years, with a median of $452500.0 in 2022.
  • Biggest YoY gain for Other Accumulated Expenses was 89.63% in 2025; the steepest drop was 89.63% in 2025.
  • Year by year, Other Accumulated Expenses stood at $457000.0 in 2022, then soared by 100.44% to $916000.0 in 2023, then soared by 42.14% to $1.3 million in 2024, then crashed by 89.63% to $135000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for LGNDZ at $135000.0 in Q4 2025, $135000.0 in Q3 2025, and $1.3 million in Q4 2024.